Validation of cellular tests for Lyme borreliosis (VICTORY) study

Abstract Background Lyme borreliosis (LB) is a tick-borne disease caused by spirochetes belonging to the Borrelia burgdorferi sensu lato species. Due to a variety of clinical manifestations, diagnosing LB can be challenging, and laboratory work-up is usually required in case of disseminated LB. Howe...

Full description

Bibliographic Details
Main Authors: F. R. van de Schoor, M. E. Baarsma, S. A. Gauw, L. A. B. Joosten, B. J. Kullberg, C. C. van den Wijngaard, J. W. Hovius
Format: Article
Language:English
Published: BMC 2019-08-01
Series:BMC Infectious Diseases
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12879-019-4323-6
id doaj-885644a690a84bd185b51796af864500
record_format Article
spelling doaj-885644a690a84bd185b51796af8645002020-11-25T01:59:32ZengBMCBMC Infectious Diseases1471-23342019-08-011911910.1186/s12879-019-4323-6Validation of cellular tests for Lyme borreliosis (VICTORY) studyF. R. van de Schoor0M. E. Baarsma1S. A. Gauw2L. A. B. Joosten3B. J. Kullberg4C. C. van den Wijngaard5J. W. Hovius6Radboudumc, Department of Internal Medicine, Radboud Center for Infectious Diseases (RCI) and Radboud Institute of Health Sciences (RIHS)Amsterdam UMC, University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam Institute of Infection and ImmunologyAmsterdam UMC, University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam Institute of Infection and ImmunologyRadboudumc, Department of Internal Medicine, Radboud Center for Infectious Diseases (RCI) and Radboud Institute of Health Sciences (RIHS)Radboudumc, Department of Internal Medicine, Radboud Center for Infectious Diseases (RCI) and Radboud Institute of Health Sciences (RIHS)National Institute for Public Health and the Environment (RIVM), Center of Infectious Disease ControlAmsterdam UMC, University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam Institute of Infection and ImmunologyAbstract Background Lyme borreliosis (LB) is a tick-borne disease caused by spirochetes belonging to the Borrelia burgdorferi sensu lato species. Due to a variety of clinical manifestations, diagnosing LB can be challenging, and laboratory work-up is usually required in case of disseminated LB. However, the current standard of diagnostics is serology, which comes with several shortcomings. Antibody formation may be absent in the early phase of the disease, and once IgG-seroconversion has occurred, it can be difficult to distinguish between a past (cured or self-cleared) LB and an active infection. It has been postulated that novel cellular tests for LB may have both higher sensitivity earlier in the course of the disease, and may be able to discriminate between a past and active infection. Methods VICTORY is a prospective two-gate case-control study. We strive to include 150 patients who meet the European case definitions for either localized or disseminated LB. In addition, we aim to include 225 healthy controls without current LB and 60 controls with potentially cross-reactive conditions. We will perform four different cellular tests in all of these participants, which will allow us to determine sensitivity and specificity. In LB patients, we will repeat cellular tests at 6 weeks and 12 weeks after start of antibiotic treatment to assess the usefulness as ‘test-of-cure’. Furthermore, we will investigate the performance of the different cellular tests in a cohort of patients with persistent symptoms attributed to LB. Discussion This article describes the background and design of the VICTORY study protocol. The findings of our study will help to better appreciate the utility of cellular tests in the diagnosis of Lyme borreliosis. Trial registration NL7732 (Netherlands Trial Register, trialregister.nl).http://link.springer.com/article/10.1186/s12879-019-4323-6Lyme diseaseBorreliosisErythema MigransBorreliaValidationCellular tests
collection DOAJ
language English
format Article
sources DOAJ
author F. R. van de Schoor
M. E. Baarsma
S. A. Gauw
L. A. B. Joosten
B. J. Kullberg
C. C. van den Wijngaard
J. W. Hovius
spellingShingle F. R. van de Schoor
M. E. Baarsma
S. A. Gauw
L. A. B. Joosten
B. J. Kullberg
C. C. van den Wijngaard
J. W. Hovius
Validation of cellular tests for Lyme borreliosis (VICTORY) study
BMC Infectious Diseases
Lyme disease
Borreliosis
Erythema Migrans
Borrelia
Validation
Cellular tests
author_facet F. R. van de Schoor
M. E. Baarsma
S. A. Gauw
L. A. B. Joosten
B. J. Kullberg
C. C. van den Wijngaard
J. W. Hovius
author_sort F. R. van de Schoor
title Validation of cellular tests for Lyme borreliosis (VICTORY) study
title_short Validation of cellular tests for Lyme borreliosis (VICTORY) study
title_full Validation of cellular tests for Lyme borreliosis (VICTORY) study
title_fullStr Validation of cellular tests for Lyme borreliosis (VICTORY) study
title_full_unstemmed Validation of cellular tests for Lyme borreliosis (VICTORY) study
title_sort validation of cellular tests for lyme borreliosis (victory) study
publisher BMC
series BMC Infectious Diseases
issn 1471-2334
publishDate 2019-08-01
description Abstract Background Lyme borreliosis (LB) is a tick-borne disease caused by spirochetes belonging to the Borrelia burgdorferi sensu lato species. Due to a variety of clinical manifestations, diagnosing LB can be challenging, and laboratory work-up is usually required in case of disseminated LB. However, the current standard of diagnostics is serology, which comes with several shortcomings. Antibody formation may be absent in the early phase of the disease, and once IgG-seroconversion has occurred, it can be difficult to distinguish between a past (cured or self-cleared) LB and an active infection. It has been postulated that novel cellular tests for LB may have both higher sensitivity earlier in the course of the disease, and may be able to discriminate between a past and active infection. Methods VICTORY is a prospective two-gate case-control study. We strive to include 150 patients who meet the European case definitions for either localized or disseminated LB. In addition, we aim to include 225 healthy controls without current LB and 60 controls with potentially cross-reactive conditions. We will perform four different cellular tests in all of these participants, which will allow us to determine sensitivity and specificity. In LB patients, we will repeat cellular tests at 6 weeks and 12 weeks after start of antibiotic treatment to assess the usefulness as ‘test-of-cure’. Furthermore, we will investigate the performance of the different cellular tests in a cohort of patients with persistent symptoms attributed to LB. Discussion This article describes the background and design of the VICTORY study protocol. The findings of our study will help to better appreciate the utility of cellular tests in the diagnosis of Lyme borreliosis. Trial registration NL7732 (Netherlands Trial Register, trialregister.nl).
topic Lyme disease
Borreliosis
Erythema Migrans
Borrelia
Validation
Cellular tests
url http://link.springer.com/article/10.1186/s12879-019-4323-6
work_keys_str_mv AT frvandeschoor validationofcellulartestsforlymeborreliosisvictorystudy
AT mebaarsma validationofcellulartestsforlymeborreliosisvictorystudy
AT sagauw validationofcellulartestsforlymeborreliosisvictorystudy
AT labjoosten validationofcellulartestsforlymeborreliosisvictorystudy
AT bjkullberg validationofcellulartestsforlymeborreliosisvictorystudy
AT ccvandenwijngaard validationofcellulartestsforlymeborreliosisvictorystudy
AT jwhovius validationofcellulartestsforlymeborreliosisvictorystudy
_version_ 1724964204881903616